Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 495, pseudogene (RNU6-495P) is classified as a pseudogene corresponding to the U6 small nuclear RNA gene family. U6 small nuclear RNA is a highly conserved, essential non-coding RNA that forms a core component of the spliceosome, the molecular complex responsible for excising introns from pre-messenger RNA during splicing[1][3]. However, RNU6-495P itself is annotated as a *pseudogene*, meaning it is a genomic locus resembling the functional gene but generally considered non-functional due to disabling mutations or lack of necessary regulatory elements[2][3]. While some pseudogenes can be transcribed and may exert regulatory effects (for example, as competing endogenous RNAs or regulators of their parent genes), there is no evidence that RNU6-495P is transcribed or functions as a protein, enzyme, transporter, or classical drug target[2]. As such, it is not considered a therapeutic target or biomarker, and no drugs are known to interact with it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 495, pseudogene (RNU6-495P).